1. >
  2. Investors
  3. >
  4. Regulated Information
  5. >
  6. Press Releases – Reg...


Found 303 Results
Page 3 of 31

Onxeo Announces the Appointment of Dr. Shefali Agarwal as the Company’s Chairwoman of the Board

Danièle Guyot-Caparros, outgoing Chairwoman, remains an independent member of the Board of Directors and Chair of the Audit Committee   […]



Onxeo: Report on the Combined General Meeting of June 10, 2021

All resolutions voted in accordance with Board of Directors’ recommendations Shefali Agarwal, MD, a clinical development expert in oncology, is […]


Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States

This new patent protects both AsiDNA™ in combination with a PARP inhibitor and the use of the combination for the […]


Onxeo Announces Formation of Scientific Advisory Committee of Leading Independent Experts

This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of […]


Onxeo’s Combined General Meeting on June 10, 2021 in camera: availability of preparatory documents and live webcast login information

Paris (France), May 21, 2021 – 5:45 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]


Publication of the 2020 Annual Financial Report

Paris (France), April 23, 2021 – 7.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]



Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update

Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch […]


Onxeo announces the success of its Rights Issue with €9.7 million raised

This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end […]


Onxeo to Present New Preclinical Data at AACR 2021

Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]

Tags: ,


B-Smart – Interview of Judith Greciet, CEO of Onxeo

Watch the interview (in French)


Page 3 of 31